@dvelarde85 Profile picture

Daniel Velarde

@dvelarde85

Cardiologo Centro Medico Nacional del Noroeste IMSS Cardiologo Centro Cardiovascular Clinica Hospital San Jose de Navojoa

Similar User
الدكتور فواز العنزي photo

@drfawazalenezi

juan ramon photo

@RamonTasmania

PMI Dallas Chapter photo

@pmidallas

Victor G. Aldana photo

@vgaldana

Jaime Angulo MD, FSCAI. photo

@jaimeanguloo

@TomasDatino photo

@TomasDatino

Chadi Alraies, MD FACC FSCAI photo

@chadialraies

Pablo Jorge photo

@PabloJ

Dr. Solís Vázquez photo

@goldenroy33

Oswaldo Lagunas photo

@oswaldolagunas

Eduardo Enriquez photo

@EnriquezEdwardo

Juan F Delgado photo

@JuanFDelgado1

Yader Sandoval photo

@yadersandoval

Karla Sue MD photo

@KarlaSue8

Karey Pérez photo

@DrKareyPerez

Pinned

"Toda intervención deber hacer que la evolución del paciente sea mejor que la espontánea"


Daniel Velarde Reposted

CLEAR results are in Colchicine is out (at least for #AMI) #AHA24 @NEJM AMI tx with colchicine did not ⤵️ incidence of the composite primary outcome (☠️from CV causes, recurrent Mi, stroke, unplanned revascularization) 📎 rb.gy/8pnnhd


Daniel Velarde Reposted

Routine Spironolactone in Acute Myocardial Infarction: @NEJM 🥸 Great trials from #AHA24: @AHASc 😱 Summary 👇👇👇

Tweet Image 1

Daniel Velarde Reposted

PRIMARY ENDPOINTS MET! We are excited to announce the positive results from OPTION Clinical Trial – the primary endpoints showed WATCHMAN FLX™ was equally effective to OACs, with a superior safety profile at 36 months, which allowed patients to eliminate continuous medication…

Tweet Image 1

Daniel Velarde Reposted

SUMMIT trial results presented at #AHA24 show tirzepatide reduced the risk of worsening #heartfailure events & improved #QoL in patients w/ #HFpEF & obesity. “Cardiologists now have an ever-expanding armamentarium to treat HFpEF,” says Dr. @ChrisKramerMD bit.ly/4hSxZ9J

Tweet Image 1

Daniel Velarde Reposted

📌 After AF ablation, LAA closure vs OAC ✔️ ⬇️risk of bleeding ✔️ 🟰efficacy to prevent stroke #afib #EPeeps #CardioTwitter #stroke @drjohnm @omwazni @Drdevignair @PrashSanders @DJ_Lakkireddy @DrJasonAndrade @DhirajGuptaBHRS @ShelleyZieroth @tomdepotter @Hragy @ftrae @drluissaenz

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Daniel Velarde Reposted

Vanish 2 trial: ablación o antiarrítmicos en pacientes con arritmias ventriculares (primera linea) ➡️La ablación mejora los resultados fundamentalmente en términos de reducción de nuevos eventos en el seguimiento. ➡️Los resultados contra sotalol son mejor que contra…

Tweet Image 1
Tweet Image 2

Daniel Velarde Reposted

El sedentarismo 🪑 tiene un efecto perjudicial en muestra salud? Por supuesto que sí @JACCJournals Nuevo estudio que lo muestra 👇👇 ▶️ > 10 horas de 🪑 aumentan un 40% el riesgo de insuficiencia cardiaca y un 54% el riesgo de muerte 🫀 🚨 Sedentarismo + ejercicio reduce el…

Tweet Image 1

Daniel Velarde Reposted

BPROAD Presented at #AHA24 Intensive SBP lowering in people with Type 2 diabetes and elevated SBP could be beneficial for reducing cardiovascular events, but increased risks of hyperkalemia and symptomatic hypotension suggest the need for careful monitoring.

Tweet Image 1

Daniel Velarde Reposted

In patients with heart failure with preserved ejection fraction and obesity, treatment with tirzepatide led to a lower risk of death from cardiovascular causes or worsening heart-failure events than placebo. Full SUMMIT trial results: nej.md/4hRGaTY #AHA24

Tweet Image 1

Daniel Velarde Reposted

#Diabetes and #obesity: leveraging heterogeneity for precision medicine This State-of-the-Art Review outlines key advances, study designs, and a roadmap to bridge research with clinical application. academic.oup.com/eurheartj/adva… #CardioMetabolic #EHJ @escardio @ESC_Journals

Tweet Image 1
Tweet Image 2

Daniel Velarde Reposted

Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1) nej.md/48VdDZp #Endocrinology

Tweet Image 1

Daniel Velarde Reposted

Staging Heart Failure with Preserved Ejection Fraction by Assessing Cardiac Chamber Involvement A paradigm shift is required to personalise care and unify our approaches to HFpEF patients for future clinical trials. ecrjournal.com/articles/stagi…

Tweet Image 1

Daniel Velarde Reposted

🌍En países de ingresos bajos y medios, el tratamiento de la #diabetes no ha avanzado al ritmo de su aumento 📈, lo que deja una creciente carga en estas regiones. Es vital priorizar programas de detección y tratamiento temprano🩸 #WorldDiabetesDay2024 thelancet.com/journals/lance…

Tweet Image 1

Daniel Velarde Reposted
Tweet Image 1

Daniel Velarde Reposted

Over 800 million adults are now living with diabetes worldwide with more than half not receiving treatment, global analysis suggests. On #WorldDiabetesDay, explore the data: hubs.li/Q02Yb3Fg0

Tweet Image 1

Daniel Velarde Reposted

A 3-year study of tirzepatide in participants with obesity and prediabetes showed substantial and sustained weight reduction and decreased risk of progression to diabetes with tirzepatide, as compared with placebo. Full SURMOUNT-1 trial results: nej.md/48VdDZp

Tweet Image 1

Daniel Velarde Reposted

Adding #enalapril to standard care during #chemotherapy did not prevent #cardiotoxicity in patients receiving high-dose anthracycline-based chemotherapy. Get the details: bit.ly/3AJecbJ #JACCCardioOnc #CardioOnc #Anthracycline #BCsm #lymsm #PROACT @akaplatini

Tweet Image 1

Daniel Velarde Reposted

🆕 Síndrome metabólico en 2024: Causas, diagnóstico y tratamiento. 📕 Nat Rev Dis Primers 📁 Resumen del artículo en cardioteca.com/cardiologia-cl…

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Daniel Velarde Reposted

Timing of intervention in patients with aortic stenosis. authors.elsevier.com/sd/article/S19…

Tweet Image 1

Loading...

Something went wrong.


Something went wrong.